Loading…
Based on limited metadata, this warning letter issued to Andapharm, LLC on February 28, 2019 concerns drug manufacturing or distribution compliance. Without access to the full warning letter text or specific subject line, the exact nature of the violations cannot be determined from the metadata provided. The FDA action falls under drug product regulation, though the specific issuing office and violation count are not available in this summary. To understand the complete regulatory concerns and required corrective actions, review of the full warning letter text would be necessary.